Abdel-Wahab N, Shah M, Lopez-Olivo M et al (2018) Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med 168(2):121–130

Article  PubMed  Google Scholar 

Abu-Sbeih H, Ali F, Naqash A et al (2019) Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J Clin Oncol 37(30):2738–2745

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abu-Sbeih H, Faleck D, Ricciuti B et al (2020) Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease. J Clin Oncol 38(6):576–583

Article  CAS  PubMed  Google Scholar 

Abu-Sbeih H, Zou F, Dutra B et al (2021) Maintenance immunosuppressive therapy with resumption of immune checkpoint inhibitor treatment to reduce recurrence of immune-mediated colitis. J Clin Oncol 39(15):2642

Article  Google Scholar 

Ahmed M, Francis G (2018) Pembrolizumab-induced microscopic colitis. Am J Gastroenterol 113(4):629–630

Article  CAS  PubMed  Google Scholar 

Bohr J, Tysk C, Eriksson S et al (1995) Collagenous colitis in Orebro, Sweden, an epidemiological study 1984–1993. Gut 37(3):394–397

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chaput N, Lepage P, Coutzac C et al (2017) Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 28(6):1368–1379

Article  CAS  PubMed  Google Scholar 

Choi K, Abu-Sbeih H, Samdani R et al (2019) Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity? Inflamm Bowel Dis 25(2):385–393

Article  PubMed  Google Scholar 

Cindoruk M, Tuncer C, Dursun A et al (2002) Increased colonic intraepithelial lymphocytes in patients with Hashimoto’s thyroiditis. J Clin Gastroenterol 34(3):237–239

Article  PubMed  Google Scholar 

Cotter T, Pardi D (2017) Current approach to the evaluation and management of microscopic colitis. Curr Gastroenterol Rep 19(2):8

Article  PubMed  Google Scholar 

Grover S, Ruan A, Srivoleti P et al (2020) Safety of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel disease and microscopic colitis. JCO Oncol Pract 16(9):933–942

Article  Google Scholar 

Günaltay S, Rademacher L, Hörnquist E et al (2017) Clinical and immunologic effects of faecal microbiota transplantation in a patient with collagenous colitis. World J Gastroenterol 23(7):1319–1324

Article  PubMed  PubMed Central  Google Scholar 

Hillock N, Heard S, Kichenadasse G et al (2017) Infliximab for ipilimumab-induced colitis: a series of 13 patients. Asia Pac J Clin Oncol 13(5):284–290

Article  Google Scholar 

Holster S, Rode J, Bohr J et al (2020) Faecal microbiota transfer in patients with microscopic colitis - a pilot study in collagenous colitis. Scand J Gastroenterol 55(12):1454–1466

Article  CAS  PubMed  Google Scholar 

Horvat TZ, Adel NG, Dang TO et al (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33(28):3193–3198

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ianiro G, Cammarota G, Valerio L et al (2012) Microscopic colitis. World J Gastroenterol 18(43):6206–6215

Article  PubMed  PubMed Central  Google Scholar 

Jegadeesan R, Liu X, Pagadala M et al (2013) Microscopic colitis: is it a spectrum of inflammatory bowel disease? World J Gastroenterol 19(26):4252–4256

Article  PubMed  PubMed Central  Google Scholar 

Johnson D, Sullivan R, Ott P et al (2016) Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2(2):234–240

Article  PubMed  Google Scholar 

Matteoni C, Goldblum J, Wang N et al (2001) Celiac disease is highly prevalent in lymphocytic colitis. J Clin Gastroenterol 32(3):225–227

Article  CAS  PubMed  Google Scholar 

Menzies A, Johnson D, Ramanujam S et al (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28(2):368–376

Article  CAS  PubMed  Google Scholar 

Michot J, Bigenwald C, Champiat S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139–148

Article  CAS  PubMed  Google Scholar 

Nielsen D, Juhl C, Chen I, et al. Immune checkpoint inhibitor-induced diarrhea and colitis: dncidence and management. A systematic review and meta-analysis. Cancer Treat Rev. 2022;109:102440.

Pardi D (2017) Diagnosis and management of microscopic colitis. Am J Gastroenterol 112(1):78–85

Article  PubMed  Google Scholar 

Park T, Cave D, Marshall C (2015a) Microscopic colitis: a review of etiology, treatment and refractory disease. World J Gastroenterol 21(29):8804–8810

Article  PubMed  PubMed Central  Google Scholar 

Park EK, Park YS, Park DR et al (2015b) Cytokine expression of microscopic colitis including interleukin-17. Gut Liver 9(3):381–387

Article  PubMed  Google Scholar 

Robert C, Schachter J, Long G (2015) Pembrolizumab versus ipilimumab in advanced melanoma. NEJM 372:2521–2532

Article  CAS  PubMed  Google Scholar 

Sharma P, Siddiqui B, Anandhan S et al (2021) The next decade of immune checkpoint therapy. Cancer Discov 11(4):838–857

Article  CAS  PubMed  Google Scholar 

Storr M (2013) Microscopic colitis: epidemiology, pathophysiology, diagnosis and current management-an update 2013. ISRN Gastroenterol 2013:352718

Article  PubMed  PubMed Central  Google Scholar 

Tagkalidis P, Gibson P, Bhathal P (2007) Microscopic colitis demonstrates a T helper cell type 1 mucosal cytokine profile. J Clin Pathol 60(4):382–387

Article  CAS  PubMed  Google Scholar 

Tang L, Wang J, Lin N et al (2021) Immune checkpoint inhibitor-associated colitis: from mechanism to management. Front Immunol 12:800879

Article  CAS  PubMed  PubMed Central  Google Scholar 

U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events. 2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf [accessed on 4 March 2022].

Wang Y, Wiesnoski D, Helmink B et al (2018) Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 24(12):1804–1808

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wickbom A, Bohr J, Nyhlin N et al (2018) Microscopic colitis in patients with ulcerative colitis or Crohn’s disease: a retrospective observational study and review of the literature. Scand J Gastroenterol 53(4):410–416

Article  PubMed  Google Scholar 

Wynat T, Fedyk E, Abhyanker B (2016) An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis 10(12):1437–1444

Article  Google Scholar 

Yeung S, Odaisat A, Chaftari P et al (2020) Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department. J Am Coll Emerg Physicians Open 1(6):1637–1659

Article  PubMed  PubMed Central  Google Scholar 

Zou F, Abu-Sbeih H, Ma W et al (2020) Association of chronic immune-mediated diarrhea and colitis with favorable cancer response. J Natl Compr Canc Netw 19(6):700–708

Article  PubMed  Google Scholar 

Zou F, Faleck D, Thomas A et al (2021) Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer 9(11):e003277

Article  PubMed  PubMed Central  Google Scholar